Breakthrough Device Route, Registries On Wish List At Senate Hearing
This article was originally published in The Gray Sheet
Executive Summary
Industry stakeholders listed their priorities to improve the medical regulatory process and research during a second hearing at the Senate Health, Education, Labor and Pensions Committee which is working on its own version of the House's 21st Century Cures bill.
You may also be interested in...
Burgess Interoperability Bill Gets Pushback From Health IT Group
While stating it supports more Congressional oversight and federal agency involvement in developing interoperability requirements for electronic health record systems, the Healthcare Information and Management Systems Society says it is concerned an interoperability bill being floated by Rep. Burgess could set the industry back.
Medicare 'Coverage With Evidence' May Rise With FDA Postmarket Emphasis
As FDA touts plans to shift clinical data requirements when possible to the postmarket phase, a top CMS official highlights the importance of the Medicare coverage with evidence development policy.
Hamburg Warns Some Of Congress’ ‘Cures’ May Be ‘Dangerous’
Outgoing FDA Commissioner also cautions against unfunded mandates in Energy & Commerce’s biomedical reform proposal.